Madhusoodhan, P Pallavi Pierro, Joanna Musante, Jordan Kothari, Prachi Gampel, Bradley Appel, Burton Levy, Adam Tal, Adit Hogan, Laura Sharma, Archana
...
Published in
Pediatric blood & cancer
Pediatric oncology patients undergoing active chemotherapy are suspected to be at a high risk for severe disease secondary to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection; however, data to support this are lacking. We aim to describe the characteristics of coronavirus disease 2019 (COVID-19) in this population and also its...
Gauci, Marie-Léa Coutzac, Clélia Houot, Roch Marabelle, Aurélien Lebbé, Céleste
Published in
European Journal of Cancer
Masemann, Dörthe Meissner, Ramona Schied, Tanja Lichty, Brian D Rapp, Ulf R Wixler, Viktor Ludwig, Stephan
Published in
Oncoimmunology
Non-small cell lung cancers (NSCLCs) establish a highly immunosuppressive tumor microenvironment supporting cancer growth. To interfere with cancer-mediated immunosuppression, selective immune-checkpoint inhibitors (ICIs) have been approved as a standard-of-care treatment for NSCLCs. However, the majority of patients poorly respond to ICI-based imm...
Pezeshki, Parmida Sadat Rezaei, Nima
Published in
Expert Opinion on Biological Therapy
Introduction Immune checkpoint inhibition (ICI) is a novel cancer immunotherapy, which is administered in patients with metastatic, refractory, or relapsed solid cancer types. Since the initiation of the Coronavirus Disease 2019 (COVID-19) pandemic, many studies have reported a higher severity and mortality rate of COVID-19 among patients with canc...
Mandala, Mario Lorigan, Paul De Luca, Matilde Bianchetti, Andrea Merelli, Barbara Bettini, Anna Cecilia Bonomi, Lucia Nahm, Sharon Vitale, Maria Grazia Negrini, Giorgia
...
Published in
Journal for Immunotherapy of Cancer
Background In ambulatory patients with cancer with asymptomatic or pauci-symptomatic SARS-CoV-2 infection, the safety of targeted therapies (TTs), chemotherapy (CT) or immune checkpoint inhibitors (ICIs) therapy is still unknown. Material and methods From the start of the first epidemic wave of SARS-CoV-2 in Bergamo, Italy, we have prospectively sc...
Fu, Yang Zheng, Yue Wang, Pei-Pei Chen, Yue-Yun Ding, Zhen-Yu
Published in
OncoTargets and therapy
Background Lymphoepithelioma-like carcinoma (LELC) is a rare malignant tumor of the lung. It is related to EB virus infection. Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) are rarely found in this disease, while high level programmed cell death ligand 1 (PD-L1) expression is observed. Here a series of patients with a...
Zhao, Xu Yang, Jing Huang, Ruoyu Guo, Mengmeng Zhou, Ya Xu, Lin
Published in
Cancer Biology & Medicine
Intermittent fasting (IF) is becoming a prevailing topic worldwide, as it can cause changes in the body’s energy metabolism processes, improve health, and affect the progression of many diseases, particularly in the circumstance of oncology. Recent research has shown that IF can alter the energy metabolism of tumor cells, thereby inhibiting tumor g...
Meng, Yue Yang, Yuebo Zhang, Yu Yang, Xiaohui Li, Xiaomao Hu, Chuan
Published in
American Journal of Translational Research
Immunotherapy is a practical and promising treatment for advanced and recurrent endometrial cancer (EC). In this study, we identified an immune-related gene (IRG) signature to predict the overall survival (OS) and response to immune checkpoints inhibitors (ICIs) in patients with EC. The RNA expression profiles of EC were obtained from The Cancer Ge...
Qu, Jingjing Mei, Quanhui Liu, Li Cheng, Tianli Wang, Peng Chen, Lijun Zhou, Jianying
Published in
Therapeutic Advances in Medical Oncology
The use of programmed cell-death protein 1 (PD-1)/programmed cell-death ligand 1 (PD-L1) inhibitors is the standard therapy for the first-line or second-line treatment of patients with non-small-cell lung cancer (NSCLC). In contrast to current traditional treatments such as chemotherapy or radiotherapy, anti-PD-1 and anti-PD-L1 treatments can direc...
Tsao, Shih Ming Wu, Tz Chin Chen, JiZhen Chang, Feichi Tsao, Thomos
Published in
Integrative Cancer Therapies
Objectives: The neutrophil-to-lymphocyte ratio (NLR) is a prognostic marker in patients with cancer receiving immunotherapy. Recent studies have shown that a high NLR was associated with a poor response and decreased survival. However, there is no intervention to reverse abnormally high NLR and improve clinical outcomes. Astragalus polysaccharide i...
